Vesugen — Khavinson bioregulator — vascular / endothelium
Vesugen (Lys-Glu-Asp) targets vascular endothelial and smooth muscle cells. Designed to restore vascular gene expression programs, improve endothelial function, and support atherosclerosis management. Reduces lipid peroxidation markers, improves microcirculation, and normalizes vascular tone in animal models. Limited human data.
Overview
This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.
Compound Class
Khavinson bioregulator — vascular / endothelium
Mechanism of Action
Vesugen (Lys-Glu-Asp) targets vascular endothelial and smooth muscle cells. Designed to restore vascular gene expression programs, improve endothelial function, and support atherosclerosis management. Reduces lipid peroxidation markers, improves microcirculation, and normalizes vascular tone in animal models. Limited human data.
Regulatory Status
Not FDA approved. Research peptide.
Evidence Level
Very Low — animal studies + small clinical observations. Limited independent human data.